We briefly summarize evidence from non-clinical and clinical studies that amylin agonism has a physiological role in glucose and body weight regulation. Next, the amylin analog pramlintide is highlighted as part of an integrated neurohormonal therapeutic approach in both diabetes and weight management. Finally, attributes of, and analoging strategies to, the amylin molecule are discussed with the goal of improving targeted properties leading to the development of an optimized therapeutic candidate.
Keywords: Pharmacotherapy, clinical studies, amylin agonism, autoradiography, receptor, Glucoregulatory Control
Rights & PermissionsPrintExport